title: Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.
abstract: Breast cancer is one of the malignant tumors with the highest morbidity and mortality. It is helpful to reduce the rate of tumor recurrence and metastasis by treating breast cancer with adjuvant chemotherapy, so as to increase the cure rate or survival of patients. In recent years, liposomes have been regarded as a kind of new carrier for targeted drugs. Being effective for enhancing drug efficacy and reducing side effects, they have been widely used for developing anticancer drugs. As a kind of anthracycline with high anticancer activity, doxorubicin can treat or alleviate a variety of malignant tumors effectively when it is used on its own or in combination with other anticancer drugs. Although liposomal doxorubicin has been extensively used in the adjuvant chemotherapy of breast cancer, its exact therapeutic efficacy and side effects have not been definitely proven. Various clinical studies have adopted different combined regimes, dosages, and staging, so their findings differ to certain extent. This paper reviews the clinical application of liposomal doxorubicin in the adjuvant chemotherapy of breast cancer and illustrates therapeutic effects and side effects of pegylated liposomal doxorubicin (PLD) and non-PLD (NPLD) in clinical research, in order to discuss the strategies for applying these drugs in such adjuvant chemotherapy, looking forward to providing references for related research and clinical treatment in terms of dosage, staging, combined regimes, and analysis methods and so on.
authors.affiliation: College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Zhao
authors.affiliation: College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China.
authors.forename: Xian-Feng
authors.initials: XF
authors.lastname: Ding
authors.affiliation: College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China.
authors.forename: Jian-Yu
authors.initials: JY
authors.lastname: Shen
authors.affiliation: Department of Tumor Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Xi-Ping
authors.initials: XP
authors.lastname: Zhang
authors.affiliation: Department of Tumor Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China.
authors.forename: Xiao-Wen
authors.initials: XW
authors.lastname: Ding
authors.affiliation: Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences, Hangzhou 310013, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
mesh_terms: D000818:Animals; D018943:Anthracyclines / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008051:Lipid Bilayers; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011092:Polyethylene Glycols / Q000737:chemistry / Q000627:therapeutic use; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D004317:Doxorubicin; D008051:Lipid Bilayers; D011092:Polyethylene Glycols; D018719:Erb-b2 Receptor Tyrosine Kinases; C506643:liposomal doxorubicin; C508053:ERBB2 protein, human
keywords: Liposomal doxorubicin; Breast cancer; Adjuvant chemotherapy; Therapeutic effect; Toxic and side effects